Work

Selective ASO-based JAK2 inhibitor for the treatment of hematological malignancies with JAK2 V617F mutation burden

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-7283

Authors: Bart Przychodzen, Sandra Smieszek

Institution: Vanda Pharmaceuticals (United States)

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417002731

Cites:

Cited by:

Related to: